Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

HC Wainwright & Co. Maintains Buy on Acurx Pharmaceuticals, Lowers Price Target to $12

Author: Benzinga Newsdesk | March 19, 2024 06:32am
HC Wainwright & Co. analyst Ed Arce maintains Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and lowers the price target from $14 to $12.

Posted In: ACXP

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist